Skip to main content
. Author manuscript; available in PMC: 2021 May 28.
Published in final edited form as: J Med Chem. 2020 May 6;63(10):5501–5525. doi: 10.1021/acs.jmedchem.0c00442

Figure 5A.

Figure 5A.

Treatment of 13a, LP411, panobinostat (Pan), vorinostat (Vor) and entinostat (Ent) in wt-p53, FLT3-ITD MV4–11 cell line for 24 h. 5B. (top) Treatment of 200 nM 13a with 3 h, 6 h, 9 h, 12 h, and 24 h, respectively. LC3-II accumulated within 12 h and is fully degraded in 24 h; (bottom) Quantification of LC3-II values were normalized to actin levels. 5C. Treatment of 13a, LP411, panobinostat (Pan), vorinostat (Vor) and entinostat (Ent) in wt-p53, wt-FLT3 RS4;11 cell line for 24 h. 5D. Treatment of 13a, LP411, panobinostat (Pan), vorinostat (Vor) and entinostat (Ent) in p53-null, wt-FLT3 HL60 cell line for 24 h.